Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $93.6 million.

  • Rocket Pharmaceuticals' Cash from Investing Activities rose 18.62% to $93.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year increase of 2.43%. This contributed to the annual value of $131.7 million for FY2024, which is 234.30% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Cash from Investing Activities is $93.6 million, which was up 194.75% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Investing Activities registered a high of $93.6 million during Q3 2025, and its lowest value of -$140.8 million during Q4 2023.
  • For the 3-year period, Rocket Pharmaceuticals' Cash from Investing Activities averaged around $9.2 million, with its median value being $31.8 million (2025).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 1,008.04% in 2021, then crashed by 743.89% in 2022.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Cash from Investing Activities stood at $16.9 million in 2021, then plummeted by 743.89% to -$108.6 million in 2022, then declined by 29.67% to -$140.8 million in 2023, then surged by 73.10% to -$37.9 million in 2024, then climbed by 18.62% to $93.6 million in 2025.
  • Its last three reported values are $93.6 million in Q3 2025, $31.8 million for Q2 2025, and -$58.0 million during Q1 2025.